Silver Book Fact

Potential cost effectiveness of shingles vaccines

The projected cost-effectiveness of a shingles vaccine for adults age 60 and older was estimated at $15,390 – $22,474 from the payer perspective, and $14,450 to $21,524 from the societal perspective.

Pellesier, James M., Marc Brisson, and Myron J. Levin. Evaluation of the Cost-Effectiveness in the United States of a Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults. Vaccine. 2007; 25(49): 8326-37. http://www.ncbi.nlm.nih.gov/pubmed/17980938

Reference

Title
Evaluation of the Cost-Effectiveness in the United States of a Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults
Publication
Vaccine
Publication Date
2007
Authors
Pellesier, James M., Marc Brisson, and Myron J. Levin
Volume & Issue
Volume 25, Issue 49
Pages
8326-37
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value
  • Future Value

Related Facts

  • Negative value of antibiotics to drug companies
    The value of an antibiotic to a drug company is negative $50 million- compared to the positive value of $1 billion for a new musculoskeletal drug.  
  • ~One-third of shingles death preventable with vaccine
    Approximately one-third of shingles deaths may be preventable through vaccination.  
  • New antibacterial agents between 1983 and 2012
    Total number of new antibacterial agents is in decline  
  • Use of shingles vaccine could save $82 to $103 million
    Use of the shingles vaccine in immunocompetent adults ages 60 and older could save between $82 and $103 million in healthcare costs associated with the diagnosis and treatment of shingles,…  
  • Only a 20% reduction in drug-resistant infections would save $3.2 – $5.2 billion each year
    A 20% reduction in drug-resistant infections would save between 5.7 and 11.3 million additional hospital days and between $3.2 and $5.2 billion in healthcare costs, each year.